Acarbose

Roasted coffee may do more than wake you up—it could help control blood sugar. Researchers discovered several new coffee compounds that inhibit α-glucosidase, a key enzyme linked to type 2 diabetes. Some of these molecules were even more potent than a common anti-diabetic drug. The study also introduced a faster, greener way to uncover health-boosting compounds in complex foods.Three newly identified compounds were found to strongly inhibit α-glucosidase, an enzyme that plays a central role in breaking down carbohydrates during digestion. Because this enzyme directly affects how quickly sugars enter the bloodstream, the discovery points to possible new functional food ingredients aimed at managing type 2 diabetes. Functional foods offer more than basic nutrition. Many contain naturally occurring molecules that may support health, including compounds with antioxidant, neuroprotective, or glucose-lowering effects. Finding these helpful substances is difficult because foods are chemically complex. Older discovery methods can be slow and inefficient, which has pushed researchers to adopt more advanced tools such as nuclear magnetic resonance (NMR) and liquid chromatography-mass spectrometry (LC-MS/MS). These techniques are especially valuable for studying roasted coffee, which contains a wide range of overlapping chemical components. Study Reveals Anti Diabetic Potential in Coffee Researchers led by Minghua Qiu at the Kunming Institute of Botany, Chinese Academy of Sciences, reported their findings in Beverage Plant Research. Their work highlights previously unknown anti-diabetic activity in coffee and adds new insight into its role as a functional food. The team designed a three-step, activity-focused process to uncover bioactive diterpene esters in roasted Coffea arabica beans. Their approach aimed to detect both common and extremely low-level compounds that could inhibit α-glucosidase, while also reducing solvent use and speeding up analysis. First, the crude diterpene extract was separated into 19 fractions using silica gel chromatography. Each fraction was then analyzed with ^1H NMR and tested for α-glucosidase inhibition. By applying cluster heatmap analysis to the ^1H NMR data, the researchers identified Fr.9-Fr.13 as the most biologically active fractions based on distinctive proton signal patterns. Further analysis of a representative sample, Fr.9, using ^13C-DEPT NMR revealed the presence of an aldehyde group, confirming earlier findings. After purification with semi-preparative HPLC, the scientists isolated three previously unknown diterpene esters, named caffaldehydes A, B, and C. Their chemical structures were verified through 1D and 2D NMR along with high-resolution mass spectrometry (HRESIMS). Stronger Effects Than a Common Diabetes Drug Although the three caffaldehydes differed in their fatty acid components (palmitic, stearic, and arachidic acids), all showed notable α-glucosidase inhibition. Their IC₅₀ values were 45.07, 24.40, and 17.50 μM respectively, indicating stronger activity than the comparison drug acarbose. To uncover additional trace compounds that were difficult to detect using NMR or HPLC alone, the team applied LC-MS/MS to combined fraction groups. They then built a molecular network using GNPS and Cytoscape. This analysis revealed three more previously unknown diterpene esters (compounds 4-6) that were closely related to caffaldehydes A-C. While they shared similar fragment patterns, these molecules contained different fatty acids (magaric, octadecenoic, and nonadecanoic acids). Searches of existing compound databases confirmed that these substances had not been reported before. Together, the results show that this integrated dereplication strategy is highly effective for identifying structurally diverse and biologically meaningful compounds in complex foods such as roasted coffee. What This Means for Functional Foods and Future Research The findings suggest new opportunities to develop coffee-based functional foods or nutraceuticals that support glucose control and may help manage diabetes. Beyond coffee, the same low-solvent, high-precision screening approach could be applied to other complex food sources to rapidly uncover health-related compounds. Future studies will focus on testing the biological effects of the newly discovered trace diterpenes and evaluating their safety and effectiveness in vivo.

Amylase is an essential enzyme found in the human body that plays a crucial role in the digestion of carbohydrates. Produced primarily in the salivary glands and pancreas, amylase breaks down complex starch molecules into simpler sugars like glucose, maltose, and dextrin. This process begins in the mouth, where salivary amylase initiates the breakdown of starches into smaller fragments. Once in the stomach, the enzyme continues its action until it reaches the small intestine, where pancreatic amylase takes over to complete the digestion process. Without amylase, the body would struggle to efficiently convert carbohydrates into usable energy, leading to potential digestive issues and nutrient deficiencies. Amylase Competitive LandscapeAccording to Patsnap Synapse, as of 27 Sep 2023, there are a total of 5 amylase drugs worldwide, from 6 organizations, covering 7 indications, and conducting 1 clinical trials. 👇Please click on the picture link below for free registration or login directly if you have freemium accounts, you can browse the latest research progress on drugs , indications, organizations, clinical trials, clinical results, and drug patents related to this target. Based on the analysis of the provided data, the current competitive landscape of target amylase indicates that companies like Anagram Therapeutics, Inc. and Propanc Biopharma, Inc. are growing rapidly in their R&D efforts. Drugs targeting amylase have been approved for indications such as Exocrine Pancreatic Insufficiency, Neoplasms, Ovarian Cancer, Solid Tumors, Pancreatic Cancer, Malabsorption Syndromes, and Gastrointestinal Diseases. Enzyme-based drugs and small molecule drugs are progressing rapidly, indicating potential competition around innovative drugs. The countries/locations with significant development in target amylase include the United States, European Union, Australia, Spain, France, Denmark, and Belgium. However, the progress in China cannot be determined based on the provided data. Overall, the target amylase market shows promising growth potential with active R&D efforts and a diverse range of indications and drug types. Key drug: AcarboseAcarbose is a small molecule drug that falls under the therapeutic areas of endocrinology and metabolic disease. It is primarily used for the treatment of diabetes mellitus, specifically type 2 diabetes. The drug targets several enzymes including alpha-amylase, GANC, MGAM, and α-glucosidase. 👇Please click on the image below to directly access the latest data (R&D Status | Core Patent | Clinical Trial | Approval status in Global countries) of this drug. The originator organization of Acarbose is Bayer AG, a well-known pharmaceutical company. The drug has reached the highest phase of approval globally, indicating its successful development and regulatory progress. Acarbose received its first approval in the United States in September 1995, making it available to patients in that country. One notable aspect of Acarbose is its regulation status, which is classified as priority review. This suggests that the drug has undergone an expedited evaluation process by regulatory authorities, possibly due to its potential benefits and urgency in addressing the medical needs of patients with type 2 diabetes. Acarbose's mechanism of action involves inhibiting the enzymes targeted, which play a role in the digestion and absorption of carbohydrates. By inhibiting these enzymes, Acarbose helps to slow down the breakdown of complex carbohydrates into simple sugars, thereby reducing the postprandial rise in blood glucose levels. This mechanism makes Acarbose a valuable treatment option for individuals with type 2 diabetes, as it helps to control their blood sugar levels. In summary, Acarbose is a small molecule drug developed by Bayer AG for the treatment of type 2 diabetes. It targets multiple enzymes involved in carbohydrate digestion and absorption, and its regulatory status as a priority review drug highlights its potential significance in managing this metabolic disease. Acarbose received its first approval in the United States in 1995 and has since been approved in other countries, including China. Its successful development and regulatory progress make it a valuable addition to the pharmaceutical industry's arsenal in combating diabetes mellitus.